Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...
MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours. This is an ASCO Meeting ...
ATOS READ THE FULL ATOS RESEARCH REPORT Business Update Abstracts Presented at ASCO 2026 In June 2026, Atossa Therapeutics, Inc. (NASDAQ: ATOS) announced that two abstracts were presented at the 2026 ...
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer Neoadjuvant approaches ...
MedPage Today on MSN
Gentler Regimen for HER2+ Breast Cancer Gets Good Grades in 5-Year Report
After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...
ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results